相关实验视频
Updated: Jun 16, 2025

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.0K
患有克罗恩氏病和乳房静脉瘤的患者可以对Upadacitinib产生反应
Lauren Loeb1, Francis A Farraye1, Sheena Crosby1
1Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, USA.
Digestive diseases and sciences
|June 14, 2025
概括
在三分之二的患有大肠静脉瘤的患者中,upadacitinib改善了克罗恩病的症状. 需要进一步的研究来了解改变解剖学如何影响这种Janus激酶抑制剂的疗效.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 简氏激酶 (JAK) 抑制剂用于炎症性肠道疾病.
- 之前的研究排除了患有大肠静脉瘤的患者.
- 在克罗恩氏病患者中使用JAK抑制剂的疗效尚未得到充分证实.
研究的目的:
- 评估克罗恩氏病 (CD) 患者的临床反应和用upadacitinib治疗的乳房结节.
- 为了确定与此患者群体中停用upadacitinib相关的因素.
主要方法:
- 在48名CD患者和用upadacitinib治疗的乳房结节瘤患者的回顾性研究中.
- 基于upadacitinib继续或停止治疗的临床反应的分析.
- 确定导致治疗停止的变量.
主要成果:
- 67%的患者 (32/48) 显示CD活动的临床改善.
- 由于各种原因,Upadacitinib在33%的患者 (16/48) 中断使用.
- 停止治疗的原因包括耐火性CD症状,不良事件和保险拒绝.
结论:
- 乌帕达西丁 (Upadacitinib) 在显著部分患有大肠静脉瘤的患者中改善了CD症状的疗效.
- 在CD患者中,胃肠道解剖学的变化可能会影响上巴西替尼的吸收和疗效.
- 需要进一步的研究来证实这些发现,并优化治疗策略.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
98
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
98
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
329
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
329
Drugs for Treatment of Diarrhea-Predominant IBS
153
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
153
Inflammatory Bowel Disease V: Surgical Management
133
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
133

